Lexaria Bioscience Corp LEXX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LEXX is a good fit for your portfolio.
News
-
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
-
Lexaria Awarded New Patents
-
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
-
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
-
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
-
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
-
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
-
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $2.24
- Day Range
- $2.18–2.28
- 52-Week Range
- $0.65–6.85
- Bid/Ask
- $2.00 / $2.18
- Market Cap
- $28.35 Mil
- Volume/Avg
- 140 / 529,878
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 48.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
Valuation
|
Metric
|
LEXX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.18 |
Price/Sales | 48.72 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LEXX
|
|---|---|
Quick Ratio | 20.57 |
Current Ratio | 21.63 |
Interest Coverage | — |
Quick Ratio
LEXX
Profitability
|
Metric
|
LEXX
|
|---|---|
Return on Assets (Normalized) | −125.45% |
Return on Equity (Normalized) | −128.81% |
Return on Invested Capital (Normalized) | −136.08% |
Return on Assets
LEXX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pyqfvvlx | Bzns | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bqrzxls | Lxjcvxz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rypngqmz | Ygfnjf | $99.5 Bil | |
MRNA
| Moderna Inc | Yhtnbqxd | Npz | $38.8 Bil | |
ARGX
| argenx SE ADR | Bgvftwvl | Dbmkc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jmxmsyym | Fgyhm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mzrbpxcg | Fphcny | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ygyvlyjy | Qcxpff | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dzxvjlmwrg | Msqkkk | $12.5 Bil | |
INCY
| Incyte Corp | Hdjvbxzq | Nvmhyv | $11.6 Bil |